Loading...
High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants.
Kügler, Jonas Schmelz, Stefan Gentzsch, Juliane Haid, Sibylle Pollmann, Erik van den Heuvel, Joop Franke, Raimo Pietschmann, Thomas Heinz, Dirk W Collins, John
Kügler, Jonas
Schmelz, Stefan
Gentzsch, Juliane
Haid, Sibylle
Pollmann, Erik
van den Heuvel, Joop
Franke, Raimo
Pietschmann, Thomas
Heinz, Dirk W
Collins, John
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2012-11-09
Submitted date
Other Titles
Abstract
Hepatitis C virus (HCV) NS3-4A protease is essential for viral replication. All current small molecular weight drugs against NS3-4A are substrate peptidomimetics that have a similar binding and resistance profile. We developed inhibitory peptides (IPs) capping the active site and binding via a novel "tyrosine" finger at an alternative NS3-4A site that is of particular interest for further HCV drug development. The peptides are not cleaved due to a combination of geometrical constraints and impairment of the oxyanion hole function. Selection and optimization through combinatorial phagemid display, protein crystallography, and further modifications resulted in a 32-amino acid peptide with a K(i) of 0.53 nm. Inhibition of viral replication in cell culture was demonstrated by fusion to a cell-penetrating peptide. Negligible susceptibility to known (A156V and R155K) resistance mutations of the NS3-4A protease was observed. This work shows for the first time that antiviral peptides can target an intracellular site and reveals a novel druggable site on the HCV protease.
Citation
High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants. 2012, 287 (46):39224-32 J. Biol. Chem.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1083-351X
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to The Journal of biological chemistry